A randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma.
Takami Sato, Marlana M. Orloff, Matias Emanuel Valsecchi, Ayako Shimada et autres
e22059 Background: Uveal melanoma is the most common primary intraocular cancer in adults. Despite successful treatment of primary tumors, up to 50% of patients later die of distant metastases. Currently, no effective adjuvant treatment is available. Presence of both monosomy 3 and …
us (code pays fourni par la source)
7 citations
Journal of Clinical Oncology